Release Details

02 June 2016

LIVANOVA PLC

LivaNova PLC (the “Company” or “LivaNova”) announces that it has filed a Form SD (Specialized Disclosure Report) in respect of conflict materials with the United States Securities And Exchange Commission on 01 June 2016.

Further details and a copy of the applicable Form SD, “Specialized Disclosure Report,” filed with the U.S. Securities & Exchange Commission, can be found at the SEC website, www.sec.gov, and the LivaNova PLC web site, www.livanova.com

About LivaNova

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit www.livanova.com, or contact:

Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com